I'm not ok with the increased # of authorized shares. We

New Post Public Reply Private Reply Replies (2) Message Board
gestalt2 Hulk767 #125777
567
I'm not ok with the increased # of authorized shares. We just voted end of last year to allow for the 200million shares. We were told they would be used sparingly. to start talking about the need for more for the same reason that was given last year is basically admitting they did not use the last 200 million shares sparingly and/or they catalyst that was to be born out of the flexibility having those shares did not happen.

We don't have any trials going on, we don't have the expenses we once had. Management needs to deliver on what the last share float increase was suppose to do. I don't care if the whole team and the BOD work for free, they owe us.

I don't understand how re-formatting the Amarex data takes this long, I don't understand why the Brazil trials were clinical holds last CC and now they are just pauses from DSMC? Also, the big one, Is why the clincal hold has not been resolve in the HIV BLA. It is just un-acceptable that this is holding everything up and they did not clearly state that they have everything together and just need the FDA to lift the Clinical hold. The management team must resolve this and I have zero interest in excuses about past management.

As for Dr Recknor's excitement about the data from the Nash trial, I was left wondering how we are just now figuring out how this drug works? It would seem that the FDA just does not look at the results of a trial, they want reasons why it worked and why different doses do different things. At this point we have done many trials and I get the feeling the FDA is frustrated asking the same questions. We have to know everything about our own product, to be still learning after 8+ years just says we did not really design the right trials and do the correct research to get FDA approval.

We paid for this, time to get our moneys worth.
2

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Updated Category News Views 2

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Continue Reading
HONA Faces Legal Heat: Investor Lawsuit Over Losses

Updated Category News Views 1

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Continue Reading
Jackson Wang's Fantasy IP Hits Hong Kong Stage

Updated Category News Views 1

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Continue Reading
Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 1

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 0

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 2

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading
AI and Storytelling Make Waves in Science Education

Updated Category News Views 2

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 2

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading

Top 5 Most Recently Viewed Articles

Legal Opportunities for Capricor Investors Facing Losses

Updated Category News Views 154

Capricor Therapeutics Faces Legal Scrutiny Capricor Therapeutics, Inc. (NASDAQ: CAPR) finds itself at the center of a significant legal issue as investors come forth with claims of securities fraud. The Rosen Law Firm, a leader in investor rights, has highlighted an important opportunity for those who purchased Capricor's securities during a specified period. This legal...

Continue Reading
Revolutionizing Therapeutics: Harbour BioMed’s AI Innovations

Updated Category News Views 221

Revolutionizing Therapeutics with AI Technology Harbour BioMed, a renowned biopharmaceutical leader, has made significant advancements in the field of drug discovery. The company specializes in developing novel antibody therapeutics primarily targeted at immunology and oncology. Their latest innovation arrives with the launch of the first fully human Generative AI HCAb...

Continue Reading
Intuit Surges in Premarket Trading Amid Strong Earnings Report

Updated Category News Views 152

Intuit Inc Sees Promising Growth in Premarket Trading Intuit Inc (NASDAQ: INTU) has experienced a significant rise in its shares during premarket trading sessions, primarily due to its impressive financial performance in the recent quarter. The company's earnings report has exceeded market expectations, showcasing its ability to thrive in a competitive landscape....

Continue Reading
HR Acuity and Labor Relations Institute Forge Dynamic Alliance

Updated Category News Views 235

HR Acuity Announces Innovative Partnership with Labor Relations Institute HR Acuity has joined forces with Labor Relations Institute Consulting Services (LRICS) to foster a new era of collaboration among labor relations professionals. This exciting initiative aims to extend support to the increasingly critical domain of labor relations, particularly as workplace dynamics...

Continue Reading
Subsea7 Excels with New Offshore Development Contract

Updated Category News Views 186

Subsea7 Engages in New Offshore Project In a significant development for Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY), the company has secured a pivotal contract with ConocoPhillips Skandinavia AS for conducting a front-end engineering and design (FEED) study. This contract pertains to the Previously Produced Fields (PPF) project offshore, which marks an exciting stride...

Continue Reading